Serge D Steinfeld, Paul Demols, Isabelle Salmon, Robert Kiss, Thierry Appelboom
{"title":"撤回两篇文章(“英夫利昔单抗在原发性Sjögren综合征患者中的应用:一项初步研究”和“英夫利昔单抗在原发性Sjögren综合征患者中的应用:一年随访”)。","authors":"Serge D Steinfeld, Paul Demols, Isabelle Salmon, Robert Kiss, Thierry Appelboom","doi":"","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"65 3","pages":"814"},"PeriodicalIF":0.0000,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Notice of retraction of two articles (“Infliximab in patients with primary Sjögren’s syndrome: a pilot study” and “Infliximab in patients with primary Sjögren’s syndrome: one-year followup”).\",\"authors\":\"Serge D Steinfeld, Paul Demols, Isabelle Salmon, Robert Kiss, Thierry Appelboom\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8405,\"journal\":{\"name\":\"Arthritis and rheumatism\",\"volume\":\"65 3\",\"pages\":\"814\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arthritis and rheumatism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis and rheumatism","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Notice of retraction of two articles (“Infliximab in patients with primary Sjögren’s syndrome: a pilot study” and “Infliximab in patients with primary Sjögren’s syndrome: one-year followup”).